{"id":"W2622354226","doi":"10.1002/hon.2437_76","title":"CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Salvage therapy; Interim analysis; Oncology; Clinical endpoint; Gemcitabine; Febrile neutropenia; Diffuse large B-cell lymphoma; Population; Neutropenia; Ibrutinib; Chemotherapy regimen; Surgery; Chemotherapy; Randomized controlled trial; Lymphoma; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01248573,0.0007720394,0.006599358,0.0005421489,0.0006217773,0.00005251732,0.001138393,0.001220483,0.0006919055],"category_scores_gemma":[0.002563737,0.0005270367,0.0008379081,0.0002907681,0.0007481996,0.0001351894,0.0003109353,0.00095459,0.00002477378],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01098941,"about_ca_system_score_gemma":0.01165039,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0823807,"about_ca_topic_score_gemma":0.08154007,"domain_scores_codex":[0.9888029,0.003468731,0.003516881,0.001302976,0.001076694,0.001831798],"domain_scores_gemma":[0.9884571,0.006811051,0.001954098,0.001612481,0.0002618112,0.0009034029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6063501,0.2278208,0.04473223,0.00190861,0.002102804,0.01940774,0.02527988,0.00004072863,0.0336473,0.0008357958,0.001340611,0.03653342],"study_design_scores_gemma":[0.9708825,0.01256649,0.003318924,0.0002276483,0.0006569503,0.0004226367,0.001005439,0.006614074,0.00258892,0.00006059828,0.001101724,0.0005541058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850906,0.002694746,0.0001003931,0.0008564405,0.0005874669,0.00824033,0.0002766891,0.00009532896,0.00205797],"genre_scores_gemma":[0.9954261,0.0007124362,0.0003952124,0.0005943723,0.0001531166,0.001563515,0.00005109588,0.00008692063,0.001017299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3645324,"threshold_uncertainty_score":0.9997181,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1357148248903003,"score_gpt":0.442831365213154,"score_spread":0.3071165403228537,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}